UK's Sovereign AI fund names its first companies, from drug discovery to chips

The government has named the first companies to be backed by its Sovereign AI programme, the £500M effort run by the Department for Science, Innovation and Technology to keep more of Britain’s AI built and owned at home. The programme’s first equity investment goes to Callosum, an AI-infrastructure startup, and six further companies will get access to some of the UK’s most powerful supercomputing: the AI-biology firm Prima Mente, the inference-cloud company Doubleword, the bioengineering startup Twig Bio, and Cosine, Cursive, and Odyssey.

The point of the announcement is that it is not another announcement. The Sovereign AI Unit was set up earlier this year with £500M and a broad remit, and the question since has been whether it would move quickly or become another well-intentioned fund that struggles to deploy. Naming a first equity bet and a cohort of companies getting real compute, aimed at problems from Alzheimer’s and Parkinson’s drug discovery to cheaper AI inference, is the government showing the programme has teeth.

It also fits a pattern we have been tracking. The same fund co-invested in Cambridge’s CuspAI and its £334M raise for AI materials discovery, and it backed London chip startup OLIX in the largest semiconductor round Europe has seen. Read together, these are the outlines of an industrial strategy: put public money and public compute behind British-founded companies working on the hard, capital-intensive layers of AI, chips, science, and infrastructure, rather than the consumer apps that attract private capital on their own.

Whether it works is a longer question. Sovereign-AI programmes are easy to launch and hard to judge, and the companies here are early, so the payoff, if it comes, is years away. Access to a supercomputer is not the same as a market, and an equity stake is not the same as a national champion. But after a year in which the UK has watched much of its AI talent and compute pulled toward better-funded American labs, a government willing to take direct stakes in the companies it wants to keep is a meaningful shift, and one worth following as the fund makes its next moves.